Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Browsing Tag

licensing

20 posts
RRoche
china germany flags
Read More

$15 billion deal: Roche bets on China — and questions Germany’s future

  • 2026-10-20
Why it matters: Roche is expanding its collaboration with Chinese pharmaceutical company Hansoh. A year after their first…
CChubb
Chubb Wealth and Hamilton Lane Form Partnership to Expand Access to Private Markets in Hong Kong
Read More

Chubb Wealth and Hamilton Lane Form Partnership to Expand Access to Private Markets in Hong Kong

  • 2026-10-12
HONG KONG, Oct. 12, 2026 /PRNewswire/ — Chubb Wealth, Chubb Group’s wealth management platform, together with leading private…
RRoche
crosshair reticle
Read More

Roche taps Chinese biotech Defand in reported $1B deal

  • 2026-10-08
Why it matters: The Swiss drugmaker is buying access to a discovery platform, with Defand tasked with finding…
NNovartis
Suzhou, Jiangsu, China
Read More

Novartis bets up to $7.8B on Abogen’s mRNA autoimmune therapy

  • 2026-10-02
Why it matters: The approach could offer a simpler way to target the B cells that drive some…
NNovartis
The Manila Times
Read More

Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs

  • 2026-10-02
Includes worldwide license to ABO2203, Abogen’s mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other…
NNovartis
light ray
Read More

Novartis licenses BoomRay radioligand asset for $900M

  • 2026-09-22
By the numbers: BoomRay will receive an undisclosed upfront payment and is eligible for development, regulatory and sales…
RRoche
dual door double colors
Read More

Roche taps Dualitas in $1B bispecific deal

  • 2026-09-17
Why it matters: Bispecific antibodies, long concentrated in oncology, are increasingly moving into autoimmune and inflammatory diseases. Roche…
RRoche
Nanjing, Jiangsu, China
Read More

Roche reloads B-cell strategy with $1.53B Simcere deal

  • 2026-09-02
Why it matters: The Swiss pharma is doubling down on therapies that achieve deeper B-cell depletion, an increasingly…
RRoche
Roche licenses Hanmi obesity drug for up to $2.3B
Read More

Roche licenses Hanmi obesity drug for up to $2.3B

  • 2026-08-24
Why it matters: The agreement adds another mechanism to Roche’s growing obesity pipeline as drugmakers look beyond weight…
RRoche
Genentech signs $515m breast cancer deal with Astex
Read More

Genentech signs $515m breast cancer deal with Astex

  • 2026-07-06
By the numbers: The R&D deal with Roche’s Genentech is worth more than $515 million plus royalties and…
RRoche
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases
Read More

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

  • 2026-06-26
SAN DIEGO, May 19, 2020 /PRNewswire/ — Vividion Therapeutics, a biotechnology company discovering and developing highly selective small…
NNovartis
Novartis signs up to $1.9bn deal to tap Antares’ undruggable-target engine
Read More

Novartis signs up to $1.9bn deal to tap Antares’ undruggable-target engine

  • 2026-06-25
Why it matters: The deal is a fresh validation point for Antares, a Scorpion Therapeutics spinout built around…
Switzerland
www.europesays.com